181955-79-3

Basic information

• Product Name: 1,4-BIS(N-BOC)PIPERAZINE-2-CARBOXYLIC ACID
• Synonyms: 1,4-DI-BOC-PIPERAZINE-2-(+/-)-CARBOXYLIC ACID;1,4-BIS(N-BOC)PIPERAZINE-2-CARBOXYLIC ACID;1,4-bis-Boc-piperazine-2-carboxylic acid;1-N-Boc-4-N-Boc-piperazine-2-carboxylic acid;Piperazine-1,2,4-tricarboxylic acid 1,4-di-tert-butyl ester;1,2,4-Piperazinetricarboxylic acid, 1,4-bis(1,1-dimethylethyl) ester;1,2,4-Piperazinetricarboxylic acid 1,4-bis(tert-butyl) ester;1,4-Di-Boc-piperazine-2-carboxylic acid, 97.5%
• CAS NO: 181955-79-3
• Molecular Formula: C₁₅H₂₆N₂O₆
• Molecular Weight: 330.38
• Mol File: 181955-79-3.mol
• Article Data: 25

Chemical Properties

• Melting Point: 142-148°C
• Boiling Point: 443.888 °C at 760 mmHg
• Flash Point: 222.256 °C
• Appearance: /
• Density: 1.201 g/cm³
• Vapor Pressure: 4.05E-09mmHg at 25°C
• Refractive Index: 1.502
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,4-BIS(N-BOC)PIPERAZINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-BIS(N-BOC)PIPERAZINE-2-CARBOXYLIC ACID(181955-79-3)
• EPA Substance Registry System: 1,4-BIS(N-BOC)PIPERAZINE-2-CARBOXYLIC ACID(181955-79-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36-43
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 181955-79-3(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C15H26N2O6/c1-14(2,3)22-12(20)16-7-8-17(10(9-16)11(18)19)13(21)23-15(4,5)6/h10H,7-9H2,1-6H3,(H,18,19)

Upstream product

• 2762-32-5 piperazine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3022-15-9 piperazine-2-carboxylic acid dihydrochloride 
• 171504-98-6 O₁,O₄-di-tert-butyl O₂-methyl piperazine-1,2,4-tricarboxylate 
• 497-19-8 sodium carbonate 
• 73371-96-7 2-<<(tert-butoxycarbonyl)oxy>imino>-2-phenylacetonitrile 

Downstream Products

• 143540-05-0 2-hydroxymethylpiperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 935544-54-0 1-phenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one 
• 935544-47-1 tert-butyl 3-oxotetrahydro-1H-oxazolo[3,4-a]pyrazine-7(3H)-carboxylate 
• 847554-73-8 tert-butyl 3-oxo-1-phenyltetrahydro-1H-oxazolo[3,4-a]pyrazine-7(3H)-carboxylate 
• 935544-52-8 tert-butyl 3-((3-fluorophenoxy)methyl)piperazine-1-carboxylate 
• 317829-98-4 1-benzyloxycarbonyl-4-(tert-butyloxycarbonyl)piperazine-2-carboxaldehyde 
• 317365-33-6 1-(benzyloxycarbonyl)-2-hydroxymethyl-4-(tert-butyloxycarbonyl)-piperazine 
• 502649-29-8 3-benzyl-piperazine-1-carboxylic acid tert-butyl ester 
• 927883-45-2 2-carbamoylpiperazine-1,4-dicarboxylic acid di-tert-butyl ester 

Relevant articles and documents

Method for synthesizing monoamine-protected piperazine-(R/S)2-formate

The invention discloses a method for synthesizing monoamine-protected piperazine-(R/S)2-formate, wherein the method comprises the steps: by using 2-piperazinecarboxylate as a raw material, protecting1,4-site amines by using different protective groups, and salifying by using different chiral amines, resolving to obtain a single chiral compound; and finally, using pyridine or DMAP and other pyridine analogues as an alkali, reacting oxalyl chloride, triphosgene, phosgene, thionyl chloride and other similar acyl chlorides in anhydrous tetrahydrofuran, 2-methyl tetrahydrofuran or toluene and other solvents, and finally adding methanol, ethanol, isopropanol, benzyl alcohol and other alcohol reagents to generate the target product capable of removing carboxylic acid ortho-amino protecting groups in a positioned manner and esterifying carboxylic acid. Amino groups on piperazine are separately protected through simple three-step reaction, chiral resolution is performed by utilizing the characteristics of acid, finally, protonated intermediates are formed through organic alkali and carboxylic acid, anhydride is formed by the protonated intermediates and ortho-amino groups, formic acid esterification is performed by utilizing alcohol to replace ring opening, and a final product is obtained.

Piperazine compound and application thereof in preparation of chemokine receptor CCR2 antagonist

The invention relates to a piperazine compound as shown in a formula (I) and an application of the piperazine compound in preparation of a chemokine receptor CCR2 antagonist or a medicine for treatingCCR2-mediated diseases.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.